Quotient Sciences Acquires Arcinova

Read the press release here

Paul Quigley, Head of Drug Substance featured in Chemistry Today

Find out more about how "Partnerships paving the way for continuous flow" by our Head of Drug Substance, Paul Quigley

Paul's article is featured in #ChemistryToday

ABSTRACT - Though continuous flow technology can significantly reduce the time and cost associated with drug development, scale-up and manufacture, there are still hurdles to its implementation in the pharmaceutical industry. Combining the flow chemistry expertise of industry and academia may provide a solution, with industry-academia collaborations producing a two-way current of knowledge that can lead to exciting innovations in drug development.

Read more here


Discover how Arcinova can help

We provide a fully integrated approach to drug development, speak to our team and discover how we can help you fast forward to market.